Core Insights - The company has announced a $100 million Solana-focused digital asset treasury strategy in partnership with Cube Group, aiming to leverage high-yield opportunities for sustainable growth [1][2][11] Group 1: Strategic Initiatives - The initiative positions the company at the forefront of institutional adoption within the Solana ecosystem, focusing on optimized entry points for long-term value creation [2][12] - The strategy is led by Cube Group, which has a proven track record in digital asset treasuries, and will manage custody, execution, and overall strategy for the company [3][4] - The company has filed a trademark application for "MULTI-DAT," indicating its strategic expansion into the digital asset sector, allowing for various financial activities including virtual currency transactions and investment portfolio oversight [5] Group 2: Digital Asset Treasury 2.0 Strategy - The strategy includes evaluating corporate treasury allocations into established digital assets to diversify holdings and enhance balance-sheet efficiency [8] - It explores participation in tokenized real-world assets to gain liquidity and transparency in a regulated environment [8] - The company plans to integrate regulated stablecoins for treasury management and cross-border activities, aiming to streamline operations and advance its core business [8] Group 3: Yield and Growth Model - The strategy aims for annualized SOL staking yields of 7-8%, with active management targeting yields of 8-20% [16] - The company emphasizes a non-dilutive growth model, utilizing Solana's staking mechanisms to enhance shareholder value without diluting existing shares [9][10] - The initiative is designed to generate superior risk-adjusted returns and contribute to the broader adoption of digital assets in mainstream finance [12]

DALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the ...

Core Insights - Mangoceuticals, Inc. has launched two new programs, MangoRx Direct and PeachesRx Direct, providing direct access to GLP-1 medications Zepbound® and Wegovy® through a secure telemedicine platform [1][2][3] Group 1: Company Overview - Mangoceuticals focuses on health and wellness products, utilizing telemedicine to offer services under the brands MangoRx and PeachesRx [1] - The company aims to simplify and sustain weight-loss treatment, offering a medication management membership for $99 per month, which includes unlimited telehealth visits and lifestyle coaching [3] - The company is positioned to address the obesity epidemic affecting 42% of U.S. adults, which costs the healthcare system over $210 billion annually [4] Group 2: Product Offerings - The GLP-1 medications will be available through Eli Lilly's LillyDirect® and Novo Nordisk's NovoCare Pharmacy, with virtual consultations and personalized treatment plans provided [2] - Medications are priced starting at $499 per month, with options for home delivery or local pharmacy pickup, and no insurance is required [3] Group 3: Market Context - The launch aligns with the White House's initiative to reduce government pricing for GLP-1 medications to $245 per month and offer $50 copays for Medicare patients with obesity starting mid-2026 [3] - The company believes it can serve millions of individuals seeking effective and affordable weight management solutions [4]